Skip to main content

Diagnosis of recurrence and follow-up using FDG-PET/CT for postoperative non-small-cell lung cancer patients

Abstract

Background

There is currently no consensus regarding the best program for postoperative follow-up and surveillance after a curative resection for non-small-cell lung cancer (NSCLC) patients. We examined the diagnostic capability of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) for detecting recurrence in postoperative NSCLC patients, and we evaluated the results of postoperative surveillance using FDG-PET/CT in asymptomatic patients.

Patients and methods

Between 2005 and 2013, 496 FDG-PET/CT examinations were performed to detect recurrences for 187 NSCLC patients who had undergone potentially curative operations at our institution. Follow-up FDG-PET/CT was performed ≥ 1 × /year in principle in 172 asymptomatic patients without clinical or radiological evidence of recurrence, and the results were retrospectively reviewed.

Results

FDG-PET/CT correctly diagnosed recurrence in 46 of 47 (97.9%) patients and 68 of 69 (98.6%) recurrent sites. The following were obtained: 97.9% sensitivity, 97.1% specificity, 92.0% positive predictive value, 99.3% negative predictive value, and 97.3% accuracy. In six patients, other diseases were detected and treated appropriately. In asymptomatic patients, the detection rate of recurrence in the stage III group was significantly higher than the detection rates in the stage I and II groups, and FDG-PET/CT performed ≤ 3 years post-resection detected significantly more FDG-positive lesions compared to that performed after 4 years.

Conclusion

FDG-PET/CT is very useful for detecting recurrence in NSCLC patients after a potentially curative operation. It might be sufficient to perform follow-up FDG-PET/CT until 3 years post-resection for advanced-stage patients. Further randomized clinical trials are needed to determine whether the early detection of recurrences leads to better prognoses.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3

References

  1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. Cancer J Clin. 2005;55:74–108.

    Article  Google Scholar 

  2. Colt HG, Murgu SD, Korst RJ, Slatore CG, Unger M, Quadrelli S. Follow-up and surveillance of the patient with lung cancer after curative-intent therapy: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e437S–e454S454S.

    Article  Google Scholar 

  3. Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. ESMO Guidelines Committee. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(suppl_4):iv1–iv21.

  4. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cell Carcinoma. ver. 7. 2015. Available at: https://www.tri-kobe.org/nccn/guideline/lung/english/non_small.pdf. Accessed: Feb 8, 2018.

  5. Keider Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, Ben-Nun A, et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med. 2004;45:1640–6.

    Google Scholar 

  6. Takenaka D, Ohno Y, Koyama H, Nogami M, Onishi Y, Matsumoto K, et al. Integrated FDG-PET/CT vs. standard radiological examinations: comparison of capability for assessment of postoperative recurrence in non-small cell lung cancer patients. Eur J Radiol. 2010;74:458–64.

    Article  Google Scholar 

  7. Kanzaki R, Higashiyama M, Maeda J, Okami J, Hosoki T, Hasegawa Y, et al. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: Experience with 241 patients. Interact Cardiovasc Thorac Surg. 2010;10:1009–144.

    Article  Google Scholar 

  8. Cho S, Lee EB. A follow-up of integrated positron emission tomography/computed tomography after curative resection of non-small cell lung cancer in asymptomatic patients. J Thorac Cardiovasc Surg. 2010;139:1447–511.

    Article  Google Scholar 

  9. Onishi Y, Ohno Y, Koyama H, Nogami M, Takenaka D, Matsumoto K, et al. Non-small cell carcinoma: comparison of postoperative intra- and extrathoracic recurrence assessment capability of qualitatively and/or quantitatively assessed FDG-PET/CT and standard radiological examinations. Eur J Radiol. 2011;79:473–9.

    Article  Google Scholar 

  10. Jiménez-Bonilla JF, Quirce R, Martínez-Rodríguez I, Banzo I, Rubio-Vassallo AS, Del Castillo-Matos R, et al. Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET/CT. Lung Cancer. 2013;81(1):71–6.

    Article  Google Scholar 

  11. Toba H, Sakiyama S, Otsuka H, Kawakami Y, Takizawa H, Kenzaki K, et al. 18F-fluorodeoxyglucose positron emission tomography/computed tomography is useful in postoperative follow-up of asymptomatic non-small-cell lung cancer patients. Interact Cardiovasc Thorac Surg. 2012;15(5):859–64.

    Article  Google Scholar 

  12. Song IH, Yeom SW, Heo S, Choi WS, Yang HC, Jheon S, et al. Prognostic factors for post-recurrence survival in patients with completely resected Stage I non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(2):262–7.

    Article  Google Scholar 

  13. Ai X, Guo X, Wang J, Stancu AL, Joslin PMN, Zhang D, et al. Targeted therapies for advanced non-small cell lung cancer. Oncotarget. 2018;9(101):37589–607.

    Article  Google Scholar 

  14. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol. 2007;2(8):706–14.

    Article  Google Scholar 

  15. Choi SH, Kim YT, Kim SK, Kang KW, Goo M, Kang CH, et al. Positron emission tomography-computed tomography for postoperative surveillance in non-small cell lung cancer. Ann Thorac Surg. 2011;92:1826–32.

    Article  Google Scholar 

  16. Sonobe M, Yamada T, Sato M, Menju T, Aoyama A, Sato T, et al. Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer. Ann Surg Oncol. 2014;21(8):2546–54.

    Article  Google Scholar 

  17. van Loon J, Grutters JP, Wanders R, Boersma L, Dingemans AM, Bootsma G, et al. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation. Eur J Cancer. 2010;46(1):110–9.

    Article  Google Scholar 

Download references

Funding

There was no funding for this study.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hiroaki Toba.

Ethics declarations

Conflict of interest

None declared.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 21 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Toba, H., Kawakita, N., Takashima, M. et al. Diagnosis of recurrence and follow-up using FDG-PET/CT for postoperative non-small-cell lung cancer patients. Gen Thorac Cardiovasc Surg 69, 311–317 (2021). https://doi.org/10.1007/s11748-020-01477-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11748-020-01477-1

Keywords

  • Follow-up
  • FDG-PET/CT
  • Non-small-cell lung cancer
  • Asymptomatic postoperative patients